Is this your brand? Sign in to claim ownership.
Sign in to claim this brandMESA BIOTECH, INC.
US
Last updated May 30, 2026
Information
- Country
- US
- Address
- —
- Website
- mesabiotech.com
- —
- —
- [email protected]
- Phone
- 858-800-4929
- PRRC Contact
- —
- EUDAMED SRN
- —
- FDA FEI Number
- —
- DUNS Number
- 056865474
Catalogue (17)
| Device | Model / Reference | Registries | Class | Status |
|---|---|---|---|---|
| Accula SARS CoV-2 Control Kit | COV4100-1 | FDA UDI | N/A | Active |
| Silaris RSV Supplemental Pack | 1040 | FDA UDI | Class II | Active |
| Accula Programming Cassette | D2001 | FDA UDI | N | Active |
| Silaris Influenza A&B Test | 1027 | FDA UDI | Class II | Active |
| SilarisTM Influenza A&B Starter Pack | 1028 | FDA UDI | Class II | Active |
| Silaris RSV Test | 1030 | FDA UDI | N/A | Active |
| Silaris Influenza A&B Control Kit | 1024 | FDA UDI | Class II | Active |
| Silaris Dock | 1026 | FDA UDI | Class II | Active |
| Accula Flu A / B Control Kit | FAB1100CW-C | FDA UDI | Class II | Active |
| Sialris Influenza A&B Supplemental Pack | 1035 | FDA UDI | Class II | Active |
| Accula Dock | D2000 | FDA UDI | N | Active |
| Accula Flu A / B Test | FAB1100CW | FDA UDI | Class II | Active |
| Silaris RSV Control Kit | 1029 | FDA UDI | Class II | Active |
| Accula SARS-CoV-2 Test | COV4100 | FDA UDI | N | Active |
| Accula Strep A Test | K201269 | FDA 510(k) | Class II | Active |
| Accula Flu A/Flu B Test | K171641 | FDA 510(k) | Class II | Active |
| Accula RSV Test | K181443 | FDA 510(k) | Class II | Active |
Related Companies
Authorised Representatives
No authorised representatives on record.
Importers
Not available yet.
Notified Bodies
Not available yet.
Authorities
Not available yet.
FDA Recalls (1)
Recalls reported by this firm to the FDA. Listed at company level — FDA recall records don't identify a specific catalogue device.
| Date | Recall No. | Class | Status | Reason |
|---|---|---|---|---|
| Apr 6, 2022 | Z-1009-2022 | — | open, classified | SARS-CoV-2 Test has an increased potential for false positive results, which may lead to a delay in correct diagnosis and treatment. |